Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
Allarity Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/27/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "FOURTH CERTIFICATE OF AMENDMENT (SERIES A PREFERRED STOCK)"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
08/02/2023 3 Vazzano Joseph Walter (Director) has filed a Form 3 on Allarity Therapeutics, Inc.
07/27/2023 8-K Resignation/termination of a director, Appointed a new director
Docs: "Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives"
07/17/2023 8-K Other Events  Interactive Data
07/14/2023 SC 13G INTRACOASTAL CAPITAL, LLC reports a 5% stake in Allarity Therapeutics, Inc.
07/11/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "THIRD CERTIFICATE OF AMENDMENT (SERIES A PREFERRED STOCK)",
"FORM OF AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT"
07/07/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
07/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering BOSTON, MA — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $4.50 per share, will be exercisable immediately and will expire five years from the initial ..."
07/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Initial Data from Allarity’ s Phase 2 Trial of IXEMPRA Indicate Potential for Improved Clinical Benefit in DRP-Selected Metastatic Breast Cancer Patients Boston, MA — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA ® in metastatic breast cancer patients selected with the DRP-IXEMPRA companion diagnostic candidate. Researchers prescreened mBC patients using Allarity’ s DRP-IXEMPRA CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP-score, and those with scores a..."
06/30/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/30/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Certificate of Designation (Series A Preferred Stock)",
"SECURED NOTE PURCHASE AGREEMENT",
"SECURED PROMISSORY NOTE",
"SECURITY AGREEMENT"
06/28/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "FOURTH CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF ALLARITY THERAPEUTICS, INC.",
"PRESS RELEASE ANNOUNCING REVERSE STOCK SPLIT"
06/07/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/01/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "FIRST CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF",
"FIRST AMENDMENT TO THE MODIFICATION AND EXCHANGE AGREEMENT",
"FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT"
05/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/26/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 SC 13G INTRACOASTAL CAPITAL, LLC reports a 4.2% stake in Allarity Therapeutics, Inc.
04/28/2023 D Form D - Notice of Exempt Offering of Securities:
04/28/2023 D Form D - Notice of Exempt Offering of Securities:
04/25/2023 8-K Quarterly results
04/20/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
04/19/2023 8-K Quarterly results
04/19/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/17/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
04/04/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03/28/2023 8-K Quarterly results
03/28/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03/20/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy